Intra-Cellular eyes broad label for bipolar depression after Phase III hit

Intra-Cellular added $903.9 million in market cap on a Phase III win for Caplyta in bipolar depression that could set the company up for a broader label in the indication than competing drugs.

The company was up $13.43 (73%) to $31.86 on Wednesday after reporting that the schizophrenia drug met the primary endpoint as an adjunctive therapy to lithium or valproate for bipolar depression in the Phase III Study 402 trial. The data support an sNDA submission planned for late 2020 or early 2021...